The Food and Drug Administration’s recent approval of new Alzheimer’s drugs sparked a flicker of hope for the millions affected by this devastating disease. But this progress casts a puzzling shadow.
The drugs come at a high cost for relatively limited benefits, offering only a brief respite in the pace of cognitive decline. This reality raises a question: Are we fixated on such marginally effective treatments at the expense of more promising preventive measures?
Let's start with the truth!
Support the Broken Science Initiative.
Subscribe today →
recent posts
Emily Kaplan challenged a room full of pharma executives and physicians with a radical message: MetFix affiliates around the world are reversing chronic disease not with new drugs, but by teaching people how their bodies actually work.
The Daley Fix #5 with Vicky Willis
